Islet Holdings Inc

OTC:ISHI

Islet Holdings Inc. engages in the research, development, and commercialization of patented technologies in the field of transplantation therapy for people with conditions of insulin-dependent diabetes. The company is headquartered in Salt Lake City, Utah and currently employs 7 full-time employees. The firm is engaged in the research, development and commercialization of patented technologies in the field of transplantation in the therapy of people with conditions of insulin-dependent diabetes. The firm is developing intellectual property relating to hemp farming and extraction of cannabidiol (CBD) from hemp. Its technology constitutes methods for isolating, culturing, cryopreservation and immune-protection (microencapsulation) of islet cells. The firm's product candidates are intended for the treatment of insulin-dependent diabetes and are intended to be administered into the patient's abdominal cavity, where the transplanted islet cells will produce insulin in response to increase in blood glucose. The primary function of microencapsulation is to protect the islets from the host's immune system. The microcapsule coating is composed of layers of biocompatible materials.